Literature DB >> 32600531

Imaging for Metastatic Renal Cell Carcinoma.

Soumya V L Vig1, Elcin Zan1, Stella K Kang2.   

Abstract

Patients with renal cell carcinoma may develop metastases after radical nephrectomy, and therefore monitoring with imaging for recurrent or metastatic disease is critical. Imaging varies with specific suspected site of disease. Computed tomography/MRI of the abdomen and pelvis are mainstay modalities. Osseous and central nervous system imaging is reserved for symptomatic patients. Radiologic reporting is evolving to reflect effects of systemic therapy on lesion morphology. Nuclear medicine studies compliment routine imaging as newer agents are evaluated for more accurate tumor staging. Imaging research aims to fill gaps in treatment selection and monitoring of treatment response in metastatic renal cell carcinoma.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CT; MRI; Metastatic disease; PET; Renal cell carcinoma

Mesh:

Year:  2020        PMID: 32600531      PMCID: PMC7327136          DOI: 10.1016/j.ucl.2020.04.005

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  28 in total

1.  Sunitinib in patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Brian I Rini; Ronald M Bukowski; Brendan D Curti; Daniel J George; Gary R Hudes; Bruce G Redman; Kim A Margolin; Jaime R Merchan; George Wilding; Michelle S Ginsberg; Jennifer Bacik; Sindy T Kim; Charles M Baum; M Dror Michaelson
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

Review 2.  The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma.

Authors:  Thomas E Hutson; Gregory R Thoreson; Robert A Figlin; Brian I Rini
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

3.  The diagnostic value of bone scan in patients with renal cell carcinoma.

Authors:  S Koga; S Tsuda; M Nishikido; Y Ogawa; K Hayashi; T Hayashi; H Kanetake
Journal:  J Urol       Date:  2001-12       Impact factor: 7.450

4.  Renal Mass and Localized Renal Cancer: AUA Guideline.

Authors:  Steven Campbell; Robert G Uzzo; Mohamad E Allaf; Eric B Bass; Jeffrey A Cadeddu; Anthony Chang; Peter E Clark; Brian J Davis; Ithaar H Derweesh; Leo Giambarresi; Debra A Gervais; Susie L Hu; Brian R Lane; Bradley C Leibovich; Philip M Pierorazio
Journal:  J Urol       Date:  2017-05-04       Impact factor: 7.450

5.  Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.

Authors:  Hyunseon C Kang; Shiva Gupta; Wei Wei; Lina Lu; Marc R Matrana; Nizar M Tannir; Haesun Choi
Journal:  AJR Am J Roentgenol       Date:  2017-10-24       Impact factor: 3.959

Review 6.  Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease.

Authors:  Nicolette K Janzen; Hyung L Kim; Robert A Figlin; Arie S Belldegrun
Journal:  Urol Clin North Am       Date:  2003-11       Impact factor: 2.241

7.  Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms.

Authors:  Angelo Baccala; Linda Sercia; Jianbo Li; Warren Heston; Ming Zhou
Journal:  Urology       Date:  2007-08       Impact factor: 2.649

8.  Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma.

Authors:  David E Kang; Richard L White; James H Zuger; Howell C Sasser; Chris M Teigland
Journal:  J Urol       Date:  2004-05       Impact factor: 7.450

Review 9.  Metastatic renal cell carcinoma: radiologic findings and assessment of response to targeted antiangiogenic therapy by using multidetector CT.

Authors:  Blanca Paño Brufau; Carmen Sebastià Cerqueda; Laura Buñesch Villalba; Rafael Salvador Izquierdo; Begoña Mellado González; Carlos Nicolau Molina
Journal:  Radiographics       Date:  2013-10       Impact factor: 5.333

10.  Role of cytokine therapy for renal cell carcinoma in the era of targeted agents.

Authors:  R Koneru; S J Hotte
Journal:  Curr Oncol       Date:  2009-05       Impact factor: 3.677

View more
  2 in total

1.  Diagnostic performance of MRI, SPECT, and PET in detecting renal cell carcinoma: a systematic review and meta-analysis.

Authors:  Qihua Yin; Huiting Xu; Yanqi Zhong; Jianming Ni; Shudong Hu
Journal:  BMC Cancer       Date:  2022-02-11       Impact factor: 4.430

2.  Establishment and Validation of a Machine Learning Prediction Model Based on Big Data for Predicting the Risk of Bone Metastasis in Renal Cell Carcinoma Patients.

Authors:  Chan Xu; Wencai Liu; Chengliang Yin; Wanying Li; Jingjing Liu; Wanli Sheng; Haotong Tang; Wenle Li; Qingqing Zhang
Journal:  Comput Math Methods Med       Date:  2022-10-03       Impact factor: 2.809

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.